Olugbeminiyi (Niyi) Fadeyi, PhD, is a principal scientist in Pfizer’s Inflammation and Immunology Medicinal Chemistry Group. Since joining Pfizer, Dr. Fadeyi has worked on projects targeting sickle cell disease, multiple chemical biology projects, and has developed a number of new synthetic methods applicable to the synthesis of drug molecules.
Originally from Nigeria, Dr. Fadeyi completed his BSc in Chemistry at Obafemi Awolowo University, Nigeria, under the direction of Professor Craig Obafemi. Following his undergraduate studies, he worked for GlaxoSmithKline Nigeria and briefly for Nigerian-German Chemicals. Dr. Fadeyi later traveled to the United States for graduate studies and obtained his MS in 2007 from Tennessee State University, under the direction of Professor Cosmas Okoro. He continued on to the doctoral program at Vanderbilt University, where under the mentorship of Professor Craig Lindsley, his research focused on the synthesis of enantioenriched betafluoroamines, aziridines and medium ring azabicycles. Dr. Fadeyi also completed the total synthesis of brevisamide, carpanone, polemannone B & C, grandisine D, B & F, amabiline and cremastrine.
In 2011, Dr. Fadeyi obtained his doctorate degree and joined Matthew Shair’s laboratories at Harvard University as a UNCF/Merck postdoctoral fellow, working on the scalable synthesis of cortistatin A.